RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc., a leader in the field of genome engineering, today announced that the United States Patent and Trademark Office (PTO) has issued a first, non-final Office Action in the reexamination proceedings for U.S. Pat. No. 7,897,372 (“the ‘372 patent”) that is owned by Cellectis SA. Importantly, this Office Action rejected every claim of the ‘372 patent as being anticipated by or obvious in view of prior art. Cellectis is afforded the opportunity to respond the PTO’s rejection of the claims of the ’372 patent. Cellectis has alleged that Precision is infringing the ‘372 patent in a lawsuit brought against Precision in March 2011.
